Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Efficacy of EXPAREL® (Bupivacaine Liposome Injectable Suspension) When Administered Via Infiltration Versus Instillation in Subjects Undergoing Bilateral Augmentation Mammoplasty

NCT01582490 is registered in ClinicalTrials.gov with Pacira Pharmaceuticals, Inc as lead sponsor.

NCT NCT01582490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01582490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Efficacy of EXPAREL® (Bupivacaine Liposome Injectable Suspension) When Administered Via Infiltration Versus Instillation in Subjects Undergoing Bilateral Augmentation Mammoplasty
Lead sponsor
Pacira Pharmaceuticals, Inc
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2012
Completion date
November 30, 2012
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mammoplasty, postoperative pain